Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
Earnings Data
Report Date
Feb 12, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-1.97Last Year’s EPS
-3.6Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and financial fortification, along with positive revenue growth and cost management. However, the net loss and the challenge of innovating within a stagnant market were concerns.Company Guidance
Completion of Phase III SENTRY Trial Enrollment
Karyopharm completed enrollment in the Phase III SENTRY trial for frontline myelofibrosis, marking a pivotal moment for the company with top-line results expected in March 2026.
Strengthened Financial Flexibility
Karyopharm secured approximately $100 million through refinancing and capital restructuring, extending their cash runway into the second quarter of 2026.
Revenue Growth
Total revenue for Q3 2025 was $44 million, an increase of 13.4% compared to Q3 2024. U.S. net product revenue for XPOVIO grew 8.5% year-over-year.
Cost Reduction Achievements
Research and development expenses decreased by 16%, and selling, general, and administrative expenses decreased by 4% compared to Q3 2024.
High Physician Intent for Combination Therapy
75% of U.S. physicians showed intent to treat with selinexor plus ruxolitinib combination therapy for myelofibrosis, indicating strong market potential.
KPTI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KPTI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 03, 2025 | $5.80 | $6.07 | +4.66% |
Aug 11, 2025 | $3.94 | $3.77 | -4.31% |
May 12, 2025 | $6.15 | $4.92 | -20.00% |
Feb 19, 2025 | $9.45 | $9.00 | -4.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Karyopharm Therapeutics (KPTI) report earnings?
Karyopharm Therapeutics (KPTI) is schdueled to report earning on Feb 12, 2026, TBA (Confirmed).
What is Karyopharm Therapeutics (KPTI) earnings time?
Karyopharm Therapeutics (KPTI) earnings time is at Feb 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KPTI EPS forecast?
KPTI EPS forecast for the fiscal quarter 2025 (Q4) is -1.97.